Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

2000
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 1
2003 8
2005 5
2006 11
2007 5
2008 1
2009 3
2010 4
2011 8
2012 5
2013 12
2014 11
2015 14
2016 11
2017 5
2018 7
2019 8
2020 4
2021 8
2022 7
2023 3
2024 5
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
The inflammatory pathogenesis of colorectal cancer.
Schmitt M, Greten FR. Schmitt M, et al. Nat Rev Immunol. 2021 Oct;21(10):653-667. doi: 10.1038/s41577-021-00534-x. Epub 2021 Apr 28. Nat Rev Immunol. 2021. PMID: 33911231 Review.
The mutational landscape of colorectal cancer (CRC) does not enable predictions to be made about the survival of patients or their response to therapy. Instead, studying the polarization and activation profiles of immune cells and stromal cells in the tumour microen …
The mutational landscape of colorectal cancer (CRC) does not enable predictions to be made about the survival of patients or their re …
Metabolism and Colorectal Cancer.
Sedlak JC, Yilmaz ÖH, Roper J. Sedlak JC, et al. Annu Rev Pathol. 2023 Jan 24;18:467-492. doi: 10.1146/annurev-pathmechdis-031521-041113. Epub 2022 Nov 2. Annu Rev Pathol. 2023. PMID: 36323004 Free PMC article. Review.
Reprogrammed metabolism is a hallmark of colorectal cancer (CRC). CRC cells are geared toward rapid proliferation, requiring nutrients and the removal of cellular waste in nutrient-poor environments. ...Here, we focus on describing the metabolism of ISCs, diets that influe …
Reprogrammed metabolism is a hallmark of colorectal cancer (CRC). CRC cells are geared toward rapid proliferation, requiring nutrient …
Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies.
Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Søreide K, et al. Cancer Epidemiol. 2016 Feb;40:39-46. doi: 10.1016/j.canep.2015.10.031. Epub 2015 Nov 24. Cancer Epidemiol. 2016. PMID: 26618334 Free article. Review.
BACKGROUND: Gastrointestinal stromal tumours (GISTs) are rare, yet the most common mesenchymal tumour within the digestive tract. ...Anatomical location of primary tumour in 9747 GISTs demonstrated gastric location as the most frequent (55.6%) followed by small bowe …
BACKGROUND: Gastrointestinal stromal tumours (GISTs) are rare, yet the most common mesenchymal tumour within the digestive tra …
Immune System, Microbiota, and Microbial Metabolites: The Unresolved Triad in Colorectal Cancer Microenvironment.
Hanus M, Parada-Venegas D, Landskron G, Wielandt AM, Hurtado C, Alvarez K, Hermoso MA, López-Köstner F, De la Fuente M. Hanus M, et al. Front Immunol. 2021 Mar 26;12:612826. doi: 10.3389/fimmu.2021.612826. eCollection 2021. Front Immunol. 2021. PMID: 33841394 Free PMC article. Review.
Most cases are sporadic, but a small proportion is hereditary, estimated at around 5-10%. In both, the tumor interacts with heterogeneous cell populations, such as endothelial, stromal, and immune cells, secreting different signals (cytokines, chemokines or growth f …
Most cases are sporadic, but a small proportion is hereditary, estimated at around 5-10%. In both, the tumor interacts with heterogen …
Regorafenib.
Ettrich TJ, Seufferlein T. Ettrich TJ, et al. Recent Results Cancer Res. 2018;211:45-56. doi: 10.1007/978-3-319-91442-8_3. Recent Results Cancer Res. 2018. PMID: 30069758 Review.
Regorafenib (BAY 73-4506, Stivarga()) is an oral diphenylurea multi-kinase inhibitor that targets angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-beta, FGFR), and oncogenic receptor tyrosine kinases (KIT, RET, and RAF). ...In addition, Regorafenib treatment resulted in a signi …
Regorafenib (BAY 73-4506, Stivarga()) is an oral diphenylurea multi-kinase inhibitor that targets angiogenic (VEGFR1-3, TIE2), stromal
Gastrointestinal stromal tumors.
Beham AW, Schaefer IM, Schüler P, Cameron S, Ghadimi BM. Beham AW, et al. Int J Colorectal Dis. 2012 Jun;27(6):689-700. doi: 10.1007/s00384-011-1353-y. Epub 2011 Nov 29. Int J Colorectal Dis. 2012. PMID: 22124674 Free PMC article. Review.
INTRODUCTION: The gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the intestinal tract, known to be refractory to conventional chemotherapy or radiation. ...Still, the only curative option for GIST is given after complete …
INTRODUCTION: The gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the intestinal t …
Sunitinib.
Heng DY, Kollmannsberger C. Heng DY, et al. Recent Results Cancer Res. 2010;184:71-82. doi: 10.1007/978-3-642-01222-8_6. Recent Results Cancer Res. 2010. PMID: 20072832 Review.
These attributes have proven to be efficacious in the treatment of metastatic renal cell carcinoma (RCC) and unresectable gastrointestinal stromal tumors (GIST). Most side effects, including hypertension, hand-foot syndrome, and diarrhea are generally well ma …
These attributes have proven to be efficacious in the treatment of metastatic renal cell carcinoma (RCC) and unresectable gastrointestina
Regorafenib for cancer.
Strumberg D, Schultheis B. Strumberg D, et al. Expert Opin Investig Drugs. 2012 Jun;21(6):879-89. doi: 10.1517/13543784.2012.684752. Expert Opin Investig Drugs. 2012. PMID: 22577890 Review.
Current clinical developments, especially in colorectal cancer (CRC) and gastrointestinal stromal tumor (GIST), are addressed. Open questions on clinically useful biomarkers predicting response with regard to a personalized therapy strategy are also be …
Current clinical developments, especially in colorectal cancer (CRC) and gastrointestinal stromal tumor (GIST), …
Exosomes in tumor-stroma crosstalk: Shaping the immune microenvironment in colorectal cancer.
Zhang Y, Huo M, Li W, Zhang H, Liu Q, Jiang J, Fu Y, Huang C. Zhang Y, et al. FASEB J. 2024 Mar 31;38(6):e23548. doi: 10.1096/fj.202302297R. FASEB J. 2024. PMID: 38491832 Review.
Colorectal cancer (CRC) is a multifaceted disease characterized by a complex interaction between tumor cells and the surrounding microenvironment. Within this intricate landscape, exosomes have emerged as pivotal players in the tumor-stroma crosstalk, influen
Colorectal cancer (CRC) is a multifaceted disease characterized by a complex interaction between tumor cells and the surroundi
Diagnostic and treatment strategy for small gastrointestinal stromal tumors.
Nishida T, Goto O, Raut CP, Yahagi N. Nishida T, et al. Cancer. 2016 Oct 15;122(20):3110-3118. doi: 10.1002/cncr.30239. Epub 2016 Aug 1. Cancer. 2016. PMID: 27478963 Free PMC article. Review.
Gastrointestinal stromal tumors (GISTs) are considered to be potentially malignant mesenchymal tumors of the gastrointestinal tract. ...For small intestinal and colorectal GISTs, surgery is indicated irrespective of size because of their
Gastrointestinal stromal tumors (GISTs) are considered to be potentially malignant mesenchymal tumors of the
128 results